Tenecteplase replacing alteplase as the standard intravenous thrombolytic for acute ischemic stroke — the single-bolus fibrinolytic agent demonstrating non-inferior efficacy with superior convenience and cost-effectiveness in major randomized trials representing the fastest-growing drug therapy segment in the global brain stroke market — creates the most commercially dynamic market...